Results 11 to 20 of about 27,659 (185)

Microglial P2Y12 deficiency/inhibition protects against brain ischemia. [PDF]

PLoS ONE, 2013
Microglia are among the first immune cells to respond to ischemic insults. Triggering of this inflammatory response may involve the microglial purinergic GPCR, P2Y12, activation via extracellular release of nucleotides from injured cells.
Corey M Webster, Masaaki Hokari, April McManus, Xian Nan Tang, Hualong Ma, Rachid Kacimi, Midori A Yenari   +6 more
doaj   +3 more sources

Platelet P2Y12 is involved in murine pulmonary metastasis. [PDF]

PLoS ONE, 2013
The involvement of platelets in tumor progression is well recognized. The depletion of circulating platelets or pharmacologic inhibitors of platelet activation decreases the metastatic potential of circulating tumor cells in metastasis mouse models.
Yanhua Wang, Yueping Sun, Ding Li, Lin Zhang, Kemin Wang, Yong Zuo, T Kent Gartner, Junling Liu   +7 more
doaj   +2 more sources

Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/percutaneous coronary intervention

Advances in Interventional Cardiology, 2017
Introduction: Periprocedural bleeding related to coronary angiography (CAG) or percutaneous coronary intervention (PCI) is associated with worse prognosis. Determining genetic variations associated with increased bleeding risk may help to identify high-
Magdalena Sionova, Peter Blasko, Stepan Jirous, David Vindis, Richard Rokyta, Zuzana Motovska   +5 more
doaj   +2 more sources

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. [PDF]

, 2022
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI).
Bhatt, Deepak, Gibson, C. Michael, Steg, Philippe G, Watanabe, Hirotoshi, Storey, Robert, Capodanno, Davide, Serruys, Patrick, Rao, Sunil V, Kastrati, Adnan, Lopes, Renato, O’donoghue, Michelle, Steg, Philippe G., Steg, Philippe Gabriel, Vranckx, Pascal, O'Donoghue, Michelle L., Angiolillo, Dominick J., Gibson, C Michael, Gwon, Hyeon-Cheol, Rao, Sunil, Rollini, Fabiana, Dangas, George, Storey, Robert F, Angiolillo, Dominick J, Bhatt, Deepak L., Rao, Sunil, V, Windecker, Stephan, Lemos, Pedro A., Bhatt, Deepak L, Storey, Robert F., Lopes, Renato D, Baber, Usman, Angiolillo, Dominick, Lemos, Pedro, Kimura, Takeshi, Collet, Jean-Philippe, Franchi, Francesco, Lopes, Renato D., Serruys, Patrick W., Lemos, Pedro A, Mehran, Roxana, Serruys, Patrick W, Valgimigli, Marco, O'Donoghue, Michelle L   +42 more
core   +2 more sources

Current status and future perspectives of platelet function-guided precision antiplatelet therapy for patients with cerebral infarction. [PDF]

Neuroprotection
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Zhu G, Chen X, Huang X, Tan Q, Cao Q, Yang Y, Lin Y, Yang J.   +7 more
europepmc   +2 more sources

D121 Located within the DRY Motif of P2Y12 Is Essential for P2Y12-Mediated Platelet Function [PDF]

, 2022
Platelets are anucleate cells that mediate hemostasis. This occurs via a primary signal that is reinforced by secreted products such as ADP that bind purinergic receptors (P2Y1 and P2Y12) on the platelet surface.
Mauri, Benjamin, Carol Dangelmaier, Kostyak, John C, Kostyak, John C., Satya P. Kunapuli, Benjamin Mauri, Kunapuli, Satya P, Patel, Akruti, John C Kostyak, Dangelmaier, Carol, Akruti Patel, Kunapuli, Satya P.   +11 more
core   +2 more sources

Association Between CYP2C19 Genotype and P2Y12 Reaction Units in Patients Receiving Clopidogrel After Acute Ischemic Stroke: A Prospective, Observational Study. [PDF]

Pharmacotherapy
ABSTRACT Background Recurrent stroke accounts for substantial morbidity and mortality worldwide, with up to 25% of ischemic strokes occurring in patients with prior strokes. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for secondary prevention after minor acute ischemic stroke (AIS) or high‐risk transient ischemic attack ...
Stone RM, Smith A, Gunter S, Weko AT, Gottschalk C, Lee C, Ramsey A, Weatherspoon MP, Worrall BB.   +8 more
europepmc   +2 more sources

P2Y12 blocker monotherapy after percutaneous coronary intervention [PDF]

, 2021
For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is ...
Verheugt, F. W. A., Wykrzykowska, J. J., van Geuns, R. -J. M., Damen, S. A. J., Woelders, E. C. I., Damman, P.   +5 more
core   +2 more sources

CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches. [PDF]

Clin Pharmacol Ther
Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is commonly used for secondary prevention following acute ischemic stroke (AIS) and neurointerventional procedures. However, the efficacy of clopidogrel is reduced in carriers of CYP2C19 no‐function alleles.
Stone RM, Hoffecker G, Schultz A, Davis BH, Bargal SA, Beitelshees AL, El Rouby N, Norris M, Rodriguez KJ, Limdi N, Cavallari LH, Lee CR.   +11 more
europepmc   +2 more sources

P2Y12-inhibitor monotherapy after coronary stenting: are all P2Y12-inhibitors equal?

, 2022
Introduction: P2Y12-inhibitor monotherapy following 1–3 months of dual antiplatelet therapy (DAPT) reduces (major) bleeding without an apparent increase in ischemic events and has therefore emerged as an alternative to 6–12 months of DAPT following ...
Küçük, I. Tarik, Appelman, Yolande, Verouden, Niels J. W., Delewi, Ronak, ten Berg, Jurriën M., Henriques, José P. S., Beijk, Marcel A. M., Claessen, Bimmer E. PM, den Hartog, Alexander W., Kikkert, Wouter J., van der Sangen, Niels M. R.   +10 more
core   +2 more sources